APEX2 and cancer: Chemotherapy targeting APE2 may thus provide a compounding effect of inducing HR deficiency in cancer cells previously proficient in HR, thus rendering them sensitive to PARP1i, Pol Theta inhibitors, and potentially to APE2 inhibition itself.